A phase 2 study of ofatumumab (Arzerra((R))) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*

Chen, CI; Paul, H; Le, LW; Wei, EN; Snitzler, S; Wang, T; Levina, O; Kakar, S; Lau, A; Queau, M; Johnston, JB; Smith, DA; Trudel, S

Chen, CI (reprint author), Ontario Canc Inst, Princess Margaret Canc Ctr, 700 Univ Ave,OPG 6-225, Toronto, ON M5M 2G9, Canada.

LEUKEMIA & LYMPHOMA, 2019; 60 (1): 92

Abstract

AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic leukemia (CLL). In this phase 2 tr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索